Affinage

NCR3LG1

Natural cytotoxicity triggering receptor 3 ligand 1 · UniProt Q68D85

Length
454 aa
Mass
50.8 kDa
Annotated
2026-04-29
59 papers in source corpus 24 papers cited in narrative 25 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

NCR3LG1 (B7-H6) is a B7-family cell-surface ligand that bridges innate immune surveillance and tumor-intrinsic oncogenic signaling. B7-H6 binds directly to the activating NK cell receptor NKp30 through CDR-like loops of its V-like domain, triggering NK cell cytotoxicity and cytokine secretion; this interaction is structurally distinct from canonical B7/CTLA-4 or PD-1/PD-L engagement (PMID:19528259, PMID:21422170). Surface expression is transcriptionally driven by c-Myc binding at the B7-H6 promoter and epigenetically regulated via BRD4-mediated histone acetylation, while post-translational N-glycosylation at N43 tunes NKp30 binding affinity and at N208 controls membrane stability; ADAM10/ADAM17-mediated ectodomain shedding generates immunosuppressive soluble B7-H6 that downregulates NKp30 on NK cells (PMID:27622013, PMID:33796404, PMID:38035117, PMID:24780758). Beyond its immune-ligand role, B7-H6 promotes tumor cell proliferation, migration, and survival through cell-autonomous activation of Ras/MEK/ERK, PI3K/Akt, and STAT3 pathways, and its expression on inflammatory monocytes, neutrophils, and virally infected cells extends its function to non-tumor immune contexts (PMID:32606790, PMID:32322592, PMID:23687088, PMID:40054066).

Mechanistic history

Synthesis pass · year-by-year structured walk · 11 steps
  1. 2009 High

    Identification of B7-H6 as the long-sought cellular ligand for the orphan activating NK receptor NKp30 established the molecular basis for NKp30-dependent tumor immunosurveillance.

    Evidence Protein binding assays, functional NK cytotoxicity/cytokine assays, flow cytometry, and expression profiling across tumor vs. normal tissues

    PMID:19528259

    Open questions at the time
    • Structural basis of interaction unknown
    • Regulation of B7-H6 expression not addressed
    • Whether soluble forms exist and their function unclear
  2. 2011 High

    Crystal structure of the NKp30–B7-H6 complex revealed an unconventional binding mode distinct from other B7-family immune checkpoint interactions, explaining NKp30's unique recognition strategy.

    Evidence X-ray crystallography of the NKp30–B7-H6 complex

    PMID:21422170

    Open questions at the time
    • Role of glycosylation in binding not resolved
    • Whether B7-H6 dimerization is functionally relevant unclear
    • Mechanism of signal transduction downstream of NKp30 engagement not addressed
  3. 2013 High

    B7-H6 expression was shown to extend beyond tumors to activated inflammatory myeloid cells, and its transcription was found to be epigenetically controlled through histone acetylation at its promoter, broadening understanding of B7-H6 regulation and its role in non-tumor immunity.

    Evidence In vitro stimulation of monocytes/neutrophils with TLR ligands and cytokines; HDAC inhibitor treatment, siRNA knockdown of HDAC2/3, ChIP for histone acetylation at B7-H6 promoter, luciferase reporters, functional NK assays

    PMID:23687088 PMID:23801635

    Open questions at the time
    • Specific transcription factors driving B7-H6 promoter activity not identified
    • In vivo relevance of myeloid B7-H6 in infection/inflammation not established
    • Whether exosomal B7-H6 is functionally active on NK cells unclear
  4. 2014 High

    Discovery that ADAM10/ADAM17 metalloproteases shed B7-H6 ectodomain from tumor cells established that soluble B7-H6 functions as an immunosuppressive decoy impairing NKp30-mediated NK activation.

    Evidence Pharmacological ADAM inhibitors, siRNA knockdown of ADAM10/17, flow cytometry, NK activation assays, ELISA for soluble B7-H6 in patient sera

    PMID:24780758

    Open questions at the time
    • Cleavage site on B7-H6 not mapped
    • Relative contributions of ADAM10 vs. ADAM17 in different tumor types not resolved
    • Whether shedding is regulated by upstream signals unknown
  5. 2015 Medium

    Multiple studies demonstrated that therapeutic stress upregulates surface B7-H6 to sensitize tumor cells to NK lysis, while chronic B7-H6 exposure (surface or soluble) in ovarian carcinoma and neuroblastoma downregulates NKp30 to exhaust NK cells, revealing B7-H6's dual role as both immune activator and suppressor depending on context.

    Evidence Drug/radiation/heat-shock treatment of tumor lines with shRNA rescue; patient tumor-associated NK cell phenotyping from peritoneal fluids; patient serum functional inhibition assays with NKp30-blocking antibodies

    PMID:25877893 PMID:26137398 PMID:26472927

    Open questions at the time
    • Signaling pathways governing stress-induced B7-H6 upregulation not identified
    • Threshold of B7-H6 exposure triggering NKp30 downregulation not quantified
    • Whether NKp30 downregulation is reversible in vivo not tested
  6. 2016 High

    Identification of c-Myc/N-Myc as direct transcriptional activators of B7-H6 provided the first specific transcription factor–promoter mechanism and linked oncogene-driven expression to NK immune recognition.

    Evidence ChIP showing c-Myc binding at B7-H6 promoter, luciferase reporter assays, siRNA/shRNA knockdown of c-Myc/N-Myc, NK degranulation assays across multiple tumor types

    PMID:27622013

    Open questions at the time
    • Whether other oncogenic transcription factors contribute to B7-H6 expression not addressed
    • Post-transcriptional regulation not explored
    • Whether c-Myc also drives B7-H6 in non-tumor cells unknown
  7. 2017 High

    HCMV proteins US18 and US20 were shown to downregulate B7-H6 via endosomal degradation, establishing a viral immune evasion mechanism targeting the NKp30–B7-H6 axis.

    Evidence Expression of individual HCMV genes in cells, flow cytometry, NK killing assays, endosomal/lysosomal degradation inhibitors

    PMID:28819195

    Open questions at the time
    • Whether other herpesviruses target B7-H6 not tested
    • Specific endosomal trafficking machinery involved not identified
    • Whether US18/US20 directly bind B7-H6 not shown
  8. 2020 Medium

    B7-H6 was found to have tumor cell-autonomous signaling functions, promoting proliferation, migration, and invasion through Ras/MEK/ERK and PI3K/Akt/c-Myc pathways independent of its NK ligand role.

    Evidence B7-H6 knockdown/overexpression in NHL and glioma cell lines, phosphoproteomics, MEK inhibitor rescue, Western blot for pathway components, xenograft models, CRISPR-Cas9 KO in 293T cells

    PMID:32322592 PMID:32606790

    Open questions at the time
    • Whether B7-H6 signals through a cis-receptor or acts receptor-independently is unknown
    • No binding partner on the tumor cell surface identified for intrinsic signaling
    • Single-lab findings for each tumor type
  9. 2021 High

    BRD4 was identified as an epigenetic reader that activates B7-H6 transcription by recognizing acetylated histones at the promoter and recruiting P-TEFb; additionally, atRA-mediated c-Myc downregulation was shown to reduce B7-H6 and confer NK resistance, unifying transcriptional and epigenetic control.

    Evidence ChIP for BRD4, histone acetylation, and P-TEFb at B7-H6 promoter/enhancer; BRD4 inhibition; metformin treatment; atRA treatment with CRISPR/siRNA controls and NK cytotoxicity assays

    PMID:33796404 PMID:34236140

    Open questions at the time
    • Whether BRD4 and c-Myc cooperate at the B7-H6 promoter or act independently not resolved
    • Enhancer–promoter looping mechanism not demonstrated
    • In vivo therapeutic validation of BRD4/c-Myc targeting to modulate B7-H6 lacking
  10. 2023 High

    Systematic glycosylation mapping revealed that conserved N-linked glycans at N43 and N208 serve distinct mechanistic roles—N43 for NKp30 binding affinity and N208 for membrane retention—explaining how post-translational modification fine-tunes both immune recognition and shedding.

    Evidence PNGase F digestion, tunicamycin treatment, single-site mutagenesis of six N-glycosylation sites, flow cytometry, NK activation assays, phylogenetic analysis

    PMID:38035117

    Open questions at the time
    • Glycan composition at each site not determined
    • Whether glycosylation status changes under stress or in different tumor types unknown
    • How N208 glycosylation mechanistically prevents shedding not resolved
  11. 2025 Medium

    SNRPA was identified as an RNA-binding protein that promotes B7-H6 pre-mRNA maturation via intron 2 splicing, connecting RNA processing to B7-H6-driven STAT3/AKT signaling and lenvatinib resistance in hepatocellular carcinoma; separately, G-CSF-induced NF-κB signaling was shown to drive B7-H6 on tumor-infiltrating neutrophils to promote their survival.

    Evidence Nanopore sequencing, RIP-seq/RIP-PCR with exon-junction primers, gain/loss-of-function for SNRPA, Western blot; G-CSF stimulation, NF-κB pathway analysis, B7-H6 antibody blockade, apoptosis assays

    PMID:40054066 PMID:40240166

    Open questions at the time
    • SNRPA–B7-H6 splicing mechanism needs independent validation
    • Whether SNRPA regulation of B7-H6 extends beyond HCC not tested
    • How B7-H6 blocks neutrophil apoptosis mechanistically (cis-signaling vs. receptor engagement) remains undefined

Open questions

Synthesis pass · forward-looking unresolved questions
  • The mechanism by which B7-H6 transduces cell-autonomous oncogenic signals (Ras/MEK/ERK, PI3K/Akt, STAT3) remains unknown—no cis-receptor, intracellular binding partner, or signaling domain has been identified to explain tumor-intrinsic B7-H6 function.
  • No intracellular binding partners identified
  • No signaling motif in B7-H6 cytoplasmic tail characterized
  • Relationship between nuclear-localized B7-H6 and transcriptional effects unexplored

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0098772 molecular function regulator activity 4 GO:0048018 receptor ligand activity 3
Localization
GO:0005886 plasma membrane 5 GO:0005576 extracellular region 4 GO:0005634 nucleus 1
Pathway
R-HSA-168256 Immune System 7 R-HSA-162582 Signal Transduction 4 R-HSA-1643685 Disease 4
Partners
ADAM10ADAM17BRD4MYCNCR3SNRPA

Evidence

Reading pass · 25 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2009 B7-H6 (NCR3LG1) is a direct cell-surface ligand for the activating NK cell receptor NKp30, binding to NKp30 and triggering NKp30-mediated NK cell cytotoxicity and cytokine secretion; B7-H6 is not detected on normal tissues but is expressed on tumor cells. Protein binding assays, functional NK cell activation assays (cytotoxicity and cytokine secretion), flow cytometry, and expression profiling of tumor vs. normal tissues The Journal of experimental medicine High 19528259
2011 Crystal structure of NKp30 in complex with B7-H6 revealed that NKp30 engages B7-H6 using both front and back β-sheets of its Ig-like domain (binding via the side and face of the β-sandwich), while B7-H6 contacts NKp30 through the CDR-like loops of its V-like domain in an antibody-like interaction distinct from CTLA-4/B7 and PD-1/PD-L complexes. X-ray crystallography of NKp30–B7-H6 complex The Journal of experimental medicine High 21422170
2014 B7-H6 ectodomain shedding from tumor cell surfaces is mediated by the metalloproteases ADAM10 and ADAM17, generating soluble B7-H6 that impairs NKp30-mediated NK cell activation; pharmacological inhibition or siRNA knockdown of ADAM10/17 increased surface B7-H6 and enhanced NK cell recognition. Pharmacological inhibitors of ADAM proteases, siRNA-mediated gene attenuation, flow cytometry, NK cell activation assays, ELISA for soluble B7-H6 in patient sera Cancer research High 24780758
2013 B7-H6 expression is induced on CD14+CD16+ proinflammatory monocytes and neutrophils upon stimulation by TLR ligands or proinflammatory cytokines (IL-1β, TNF-α); in these conditions a soluble form is also produced, associated with membrane vesicles in the exosomal fraction. In vitro stimulation of primary monocytes/neutrophils, flow cytometry for surface B7-H6, ELISA for soluble B7-H6, exosome fractionation/sedimentation Blood High 23687088
2013 B7-H6 mRNA and surface protein expression in tumor cells is regulated epigenetically through histone acetylation at the B7-H6 promoter; pan- or class I HDAC inhibitors (or siRNA knockdown of HDAC2/3) downregulate B7-H6, reducing histone acetylation at the promoter and decreasing NKp30-dependent NK effector functions. HDAC inhibitor treatment, siRNA knockdown of HDAC2/3, luciferase reporter assays, chromatin immunoprecipitation (ChIP), flow cytometry, NK cell functional assays Blood High 23801635
2016 The proto-oncogene c-Myc (and N-Myc) directly drives B7-H6 transcription by binding a functional site in the B7-H6 promoter; pharmacological inhibition or siRNA/shRNA knockdown of c-Myc or N-Myc significantly decreases B7-H6 expression and impairs NKp30-mediated NK cell degranulation. Luciferase reporter assays, chromatin immunoprecipitation (ChIP), siRNA/shRNA knockdown of c-Myc/N-Myc, pharmacological inhibition, flow cytometry, NK cell degranulation assays Oncoimmunology High 27622013
2016 Crystal structure of antibody 17B1.3 in complex with B7-H6 ectodomain at 2.5 Å resolution showed the antibody binds a site completely distinct from the NKp30-binding site on B7-H6; structure-based mutagenesis of potential B7-H6 dimerization sites did not diminish NKp30-mediated cell activation, indicating the antibody inhibits NK cell activation by sterically interfering with cell–cell contacts rather than directly blocking the NKp30–B7-H6 interaction. X-ray crystallography at 2.5 Å, structure-based site-directed mutagenesis, NK cell activation assays Journal of molecular biology High 27663271
2017 Human cytomegalovirus (HCMV) upregulates B7-H6 expression following infection, but HCMV genes US18 and US20 downregulate B7-H6 surface expression via an endosomal degradation mechanism to evade NK cell recognition through NKp30. HCMV infection of cells, expression of individual viral genes (US18, US20), flow cytometry for surface B7-H6, NK cell killing assays, inhibitors of endosomal/lysosomal degradation Scientific reports High 28819195
2015 Chronic engagement of NKp30 by surface or soluble B7-H6 on ovarian carcinoma cells leads to downregulation of NKp30 expression on tumor-associated NK cells, impairing their IFN-γ production and cytolytic function. Flow cytometry of tumor-associated NK cells from peritoneal fluids, functional cytotoxicity and cytokine assays, correlation with surface/soluble B7-H6 levels in peritoneal fluid Oncoimmunology Medium 26137398
2015 Soluble B7-H6 in serum of high-risk neuroblastoma patients inhibits NK cell functions in vitro, correlating with NKp30 downregulation; NB cells expressing surface B7-H6 stimulate NK cells in an NKp30-dependent manner. In vitro NK cell functional assays with patient serum, NKp30-blocking antibodies, flow cytometry, ELISA for soluble B7-H6 Science translational medicine Medium 25877893
2015 Tumor therapeutic stressors (cisplatin, 5-fluorouracil, radiation, heat shock, TNF-α) upregulate B7-H6 surface expression on tumor cells, enhancing their susceptibility to NKp30-mediated NK cell lysis; B7-H6 shRNA knockdown dampened this sensitization. Drug/radiation/heat-shock treatment of tumor cell lines, flow cytometry for B7-H6, NK cell cytotoxicity assays, shRNA knockdown The Journal of biological chemistry Medium 26472927
2021 Soluble B7-H6 (sB7-H6) inhibits NK cell-mediated target cell killing and is associated with diminished cell surface expression of NKG2D and NCRs (NKp30, NKp46); in contrast to BAG6, B7-H6 is only marginally released in association with extracellular vesicles and EV-associated B7-H6 does not stimulate NK killing. Recombinant ligand production in HEK293 cells, NK cell killing assays, flow cytometry for receptor expression, nano flow cytometry of EVs, EV isolation and characterization International journal of molecular sciences Medium 33671836
2021 BRD4, an epigenetic reader, activates B7-H6 transcription in AML cells: histone acetylation mediated by CBP30/P300 facilitates BRD4 binding to the B7-H6 promoter, which recruits P-TEFb to phosphorylate RNA polymerase II; BRD4 also co-binds with JMJD6 at a distal B7-H6 enhancer. Metformin reduces histone acetylation at the B7-H6 promoter, impairing BRD4 binding and inhibiting B7-H6 expression. BRD4-specific inhibition, ChIP for BRD4/histone acetylation/P-TEFb at B7-H6 promoter/enhancer, flow cytometry, RT-PCR, metformin treatment, B7-H6 knockdown apoptosis assays Oncoimmunology High 33796404
2023 B7-H6 contains six functional N-linked glycosylation sites; N43 and N208 glycosylation are conserved in jawed vertebrates and are essential for NK cell activation. Mechanistically, N43 glycosylation contributes to B7-H6/NKp30 binding affinity, while N208 glycosylation is required for membrane stability (lack of N208 leads to B7-H6 shedding from the membrane). PNGase F digestion, tunicamycin blockage, single-site mutagenesis, SDS-PAGE/Western blot, flow cytometry, NK cell activation assays, phylogenetic and structural analysis Frontiers in immunology High 38035117
2019 B7-H6 is strongly expressed on the surface of CD4+ T cells infected with HIV-2, and chronic NKp30 engagement by this surface B7-H6 leads to downregulation of NKp30 on NK cells, impairing their cytolytic function while increasing IFN-γ overproduction. Flow cytometry phenotyping of NK cells and target cells from HIV-2 patients, functional killing assays against B7-H6-expressing targets AIDS Medium 30325780
2020 B7-H6 promotes tumor cell proliferation, migration, and invasion in non-Hodgkin lymphoma via the Ras/MEK/ERK signaling pathway; B7-H6 knockdown inhibited Ras/MEK/ERK phosphorylation, and MEK inhibitor AZD8330 reversed migration/invasion induced by B7-H6. B7-H6 knockdown and overexpression in NHL cell lines, quantitative phosphoproteomics, Western blot for Ras/MEK/ERK pathway, MEK inhibitor rescue, in vivo xenograft model, CCK-8 and Transwell assays OncoTargets and therapy Medium 32606790
2020 B7-H6 preferentially expressed in glioma stem-like cells (GSLCs) promotes proliferation via the c-Myc/RNMT axis; B7-H6 knockdown decreased c-Myc expression, inhibited PI3K/Akt and ERK/MAPK signaling, and specifically reduced RNMT (RNA guanine-7 methyltransferase) expression among co-expressed genes. CRISPR-Cas9 knockout of B7-H6 in 293T cells also suppressed proliferation. siRNA knockdown, CRISPR-Cas9 knockout, Western blot for c-Myc/PI3K/Akt/ERK, TCGA co-expression analysis, flow cytometry, CCK-8 proliferation assays Journal of immunology research Medium 32322592
2021 B7-H6 undergoes nuclear translocation in T-lymphoblastic lymphoma (T-LBL) cells, with a specific nuclear localization sequence identified in the C-terminus; B7-H6 depletion in Jurkat cells impaired proliferation, migration, and invasion, and RNA-seq revealed differential expression of RAG-1 as a potential downstream mediator. Immunohistochemistry showing nuclear localization, nuclear localization sequence analysis, B7-H6 depletion, RNA sequencing, functional cell assays Annals of translational medicine Medium 33708955
2025 SNRPA promotes B7-H6 expression in hepatocellular carcinoma by directly binding B7-H6 pre-mRNA and facilitating its maturation through intron 2 splicing; SNRPA-driven B7-H6 upregulation activates the B7-H6–STAT3/AKT signaling axis, promoting G1-S transition and inhibiting apoptosis, and confers resistance to lenvatinib. Nanopore full-length cDNA sequencing, RNA-binding protein immunoprecipitation sequencing, RIP-PCR with exon-exon and exon-intron junction primers, gain/loss-of-function experiments, Western blot for STAT3/AKT, flow cytometry, drug sensitivity assays Bioscience trends Medium 40240166
2021 B7-H6 knockdown in AML (HEL-R) cells induces apoptosis, and high B7-H6 expression in AML activates anti-apoptotic signaling; the BRD4–B7-H6 regulatory axis is linked to the STAT3 pathway activity in these cells. B7-H6 knockdown (siRNA), flow cytometry for apoptosis, Western blot, correlation with BRD4 inhibition Oncoimmunology Medium 33796404
2015 NKp30-B7-H6 interaction in HBV-related acute-on-chronic liver failure leads to upregulation of IL-32 in NK cells; IL-32 in turn induces apoptosis of hepatocytes in a dose-dependent manner, establishing a mechanistic link between B7-H6 engagement and hepatocyte damage via IL-32. Co-culture of NK-92 cells with B7-H6-expressing hepatocytes, anti-NKp30 antibody stimulation, flow cytometry for IL-32 in NK cells, Annexin V/PI apoptosis assay of hepatocytes treated with IL-32, immunohistochemistry in patient liver samples PloS one Medium 26241657
2021 atRA-induced downregulation of c-Myc reduces B7-H6 transcription in leukemia cells, rendering them resistant to NKp30/B7-H6-dependent NK cell killing; epigenetic modifications (DNA methylation, HDAC) were not responsible, as their inhibitors could not restore B7-H6 expression. CRISPR/Cas9 B7-H6 knockdown, siRNA c-Myc knockdown, atRA treatment, real-time PCR, flow cytometry, Western blot, NK cell cytotoxicity assays, HDAC/DNA methylation inhibitor controls Cancer communications Medium 34236140
2024 CRISPR-mediated knockout of B7-H6 in CD4+ T cells reduced NK cell responses to HIV-1-infected cells, confirming the NKp30:B7-H6 receptor–ligand pair as functionally required for NK recognition of HIV-infected cells. CRISPR editing of CD4+ T cells to knockout B7-H6, NK cell functional assays, NKp30 overexpression in NK cells bioRxivpreprint Medium bio_10.1101_2024.06.24.600449
2023 B7-H6 promotes medulloblastoma cell migration and invasion by activating c-MYC expression, which in turn drives F-actin cytoskeletal rearrangement and upregulates MMP-2 and MMP-9. siRNA knockdown and plasmid overexpression of B7-H6, Transwell migration/invasion assays, Western blot for c-MYC/MMP-2/MMP-9, immunofluorescence staining for F-actin Medical oncology Low 36692844
2025 G-CSF derived from gastric cancer tumors induces B7-H6 expression on neutrophils via NF-κB signaling pathway activation; B7-H6 on tumor-infiltrating neutrophils promotes their survival by blocking apoptosis, as B7-H6 blockade accelerated neutrophil apoptosis and shortened their lifespan. Flow cytometry phenotyping, in vitro neutrophil stimulation with G-CSF and tumor-conditioned supernatants, NF-κB pathway analysis, B7-H6 blockade with antibodies, apoptosis assays Neoplasia Medium 40054066

Source papers

Stage 0 corpus · 59 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2009 The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. The Journal of experimental medicine 544 19528259
2014 Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30. Cancer research 171 24780758
2015 B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape. Oncoimmunology 151 26137398
2015 Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients. Science translational medicine 123 25877893
2013 Induction of B7-H6, a ligand for the natural killer cell-activating receptor NKp30, in inflammatory conditions. Blood 119 23687088
2013 Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. Blood 113 23801635
2011 Structure of the human activating natural cytotoxicity receptor NKp30 bound to its tumor cell ligand B7-H6. The Journal of experimental medicine 100 21422170
2011 B7-H6/NKp30 interaction: a mechanism of alerting NK cells against tumors. Cellular and molecular life sciences : CMLS 88 21877119
2015 Tumor Therapeutics Work as Stress Inducers to Enhance Tumor Sensitivity to Natural Killer (NK) Cell Cytolysis by Up-regulating NKp30 Ligand B7-H6. The Journal of biological chemistry 77 26472927
2015 B7-H6 expression correlates with cancer progression and patient's survival in human ovarian cancer. International journal of clinical and experimental pathology 64 26464699
2016 The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells. Oncoimmunology 48 27622013
2012 Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity. Journal of immunology (Baltimore, Md. : 1950) 47 23066150
2016 Knockdown of B7-H6 inhibits tumor progression and enhances chemosensitivity in B-cell non-Hodgkin lymphoma. International journal of oncology 41 26891663
2020 Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement. Journal of immunology (Baltimore, Md. : 1950) 40 33268483
2017 Human cytomegalovirus escapes immune recognition by NK cells through the downregulation of B7-H6 by the viral genes US18 and US20. Scientific reports 40 28819195
2017 High expression of B7-H6 in human glioma tissues promotes tumor progression. Oncotarget 39 28415577
2014 B7-H6 expression in non-small cell lung cancers. International journal of clinical and experimental pathology 39 25400778
2018 B7-H6 expression is induced by lipopolysaccharide and facilitates cancer invasion and metastasis in human gliomas. International immunopharmacology 36 29679856
2020 Anti-fouling SERS-based immunosensor for point-of-care detection of the B7-H6 tumor biomarker in cervical cancer patient serum. Analytica chimica acta 35 33161972
2017 The B7 Family Member B7-H6: a New Bane of Tumor. Pathology oncology research : POR 35 29086181
2018 Long non-coding RNA LINC00673 promotes breast cancer proliferation and metastasis through regulating B7-H6 and epithelial-mesenchymal transition. American journal of cancer research 34 30094100
2020 Preferential Expression of B7-H6 in Glioma Stem-Like Cells Enhances Tumor Cell Proliferation via the c-Myc/RNMT Axis. Journal of immunology research 30 32322592
2021 Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 25 33839362
2017 Clinical significance of novel costimulatory molecule B7-H6 in human breast cancer. Oncology letters 24 28789456
2021 Secreted Ligands of the NK Cell Receptor NKp30: B7-H6 Is in Contrast to BAG6 Only Marginally Released via Extracellular Vesicles. International journal of molecular sciences 22 33671836
2020 Immunological role and underlying mechanisms of B7-H6 in tumorigenesis. Clinica chimica acta; international journal of clinical chemistry 22 31904350
2022 The potential of B7-H6 as a therapeutic target in cancer immunotherapy. Life sciences 21 35697295
2018 B7-H6 expression in human hepatocellular carcinoma and its clinical significance [corrected]. Cancer cell international 19 30186042
2022 A Novel B7-H6-Targeted IgG-Like T Cell-Engaging Antibody for the Treatment of Gastrointestinal Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 17 36166004
2020 B7-H6 Promotes Cell Proliferation, Migration and Invasion of Non-Hodgkin Lymphoma via Ras/MEK/ERK Pathway Based on Quantitative Phosphoproteomics Data. OncoTargets and therapy 16 32606790
2020 Positive staining of the immunoligand B7-H6 in abnormal/transformed keratinocytes consistently accompanies the progression of cervical cancer. BMC immunology 15 32138659
2020 B7-H6, an immunoligand for the natural killer cell activating receptor NKp30, reveals inhibitory effects on cell proliferation and migration, but not apoptosis, in cervical cancer derived-cell lines. BMC cancer 15 33172426
2015 NKP30-B7-H6 Interaction Aggravates Hepatocyte Damage through Up-Regulation of Interleukin-32 Expression in Hepatitis B Virus-Related Acute-On-Chronic Liver Failure. PloS one 15 26241657
2020 Expression of a novel immune checkpoint B7-H6 ligand in human small cell lung cancer. Annals of translational medicine 14 32566616
2020 B7-H6 as an efficient target for T cell-induced cytotoxicity in haematologic malignant cells. Investigational new drugs 14 32770284
2019 B7-H6-mediated downregulation of NKp30 in natural killer cells contributes to HIV-2 immune escape. AIDS (London, England) 14 30325780
2016 Structural Insights into the Inhibitory Mechanism of an Antibody against B7-H6, a Stress-Induced Cellular Ligand for the Natural Killer Cell Receptor NKp30. Journal of molecular biology 14 27663271
2021 Immune checkpoint molecules B7-H6 and PD-L1 co-pattern the tumor inflammatory microenvironment in human breast cancer. Scientific reports 12 33824367
2021 B7-H6 is a new potential biomarker and therapeutic target of T-lymphoblastic lymphoma. Annals of translational medicine 11 33708955
2021 Bromodomain protein BRD4 is an epigenetic activator of B7-H6 expression in acute myeloid leukemia. Oncoimmunology 11 33796404
2024 Harnessing B7-H6 for Anticancer Immunotherapy: Expression, Pathways, and Therapeutic Strategies. International journal of molecular sciences 8 39408655
2015 Expression, crystallization and X-ray diffraction analysis of a complex between B7-H6, a tumor cell ligand for the natural cytotoxicity receptor NKp30, and an inhibitory antibody. Acta crystallographica. Section F, Structural biology communications 8 26057798
2023 Deficiency of N-linked glycosylation impairs immune function of B7-H6. Frontiers in immunology 7 38035117
2021 All-trans retinoic acid induces leukemia resistance to NK cell cytotoxicity by down-regulating B7-H6 expression via c-Myc signaling. Cancer communications (London, England) 7 34236140
2021 Sevoflurane impedes glioma progression via regulating circ_0000215/miR-1200/NCR3LG1 axis. Metabolic brain disease 7 34460046
2019 Expression of B7-H6 in chronic myeloid leukemia and its clinical significance. International journal of clinical and experimental pathology 7 31933861
2021 B7-H6 as a Diagnostic Biomarker for Cervical Squamous Cell Carcinoma. Genetic testing and molecular biomarkers 5 34280008
2018 Correction to: Expression of B7-H6 expression in human hepatocellular carcinoma and its clinical significance. Cancer cell international 4 30214376
2025 Dual T/NK cell engagement via B7-H6-targeted bispecific antibodies and IL-15 eradicates chemo-resistant solid tumors. Frontiers in immunology 2 40873574
2024 Enhancing NK cell-mediated tumor killing of B7-H6+ cells with bispecific antibodies targeting allosteric sites of NKp30. Molecular therapy. Oncology 2 39811682
2023 B7-H6 enhances F-actin rearrangement by targeting c-MYC activation to promote medulloblastoma migration and invasion. Medical oncology (Northwood, London, England) 2 36692844
2025 Expression, regulation, function and clinical significance of B7-H6 on neutrophils in human gastric cancer. Neoplasia (New York, N.Y.) 1 40054066
2025 SNRPA promotes hepatocellular carcinoma proliferation and lenvatinib resistance via B7-H6-STAT3/AKT axis by facilitating B7-H6 pre-mRNA maturation. Bioscience trends 1 40240166
2023 Affinity Maturation of the Natural Ligand (B7-H6) for Natural Cytotoxicity Receptor NKp30 by Yeast Surface Display. Methods in molecular biology (Clifton, N.J.) 1 37405651
2020 The B7 family molecules in oral squamous cell carcinoma: a systematic review. Part II: B7-1, B7-2, B7-H2, B7-H3, B7-H4, B7-H5 (VISTA), B7-H6 and B7-H7. Postepy dermatologii i alergologii 1 41001137
2016 [Elevated expression of B7-H6 in U87 cells-derived glioma stem like cells is associated with biological characteristics]. Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology 1 27609569
2014 Allogeneic and xenogeneic anti-tumor effect of callithrix jacchus natural killer cells is dependent on NKp30 and B7-H6 interaction. Journal of biological regulators and homeostatic agents 1 25001651
2025 Association between elevated serum soluble B7-H6 and infection in hemodialysis patients. Clinical and experimental nephrology 0 40425991
2022 Erratum: Long non-coding RNA LINC00673 promotes breast cancer proliferation and metastasis through regulating B7-H6 and epithelial-mesenchymal transition. American journal of cancer research 0 35261813